PharmaTher Provides Update on FDA New Drug Application for Ketamine
Portfolio Pulse from
PharmaTher plans to submit a minor amendment to the FDA's Complete Response Letter by February 2025, aiming for ketamine approval in Q2 2025.
February 12, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PharmaTher is working towards FDA approval for ketamine, with a minor amendment to be submitted by February 2025, aiming for approval in Q2 2025.
The news indicates a clear timeline for PharmaTher's ketamine approval process, which could positively impact investor sentiment and stock price as the approval date approaches.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100